Skip to content
HomeLatest newsCaring & givingBridge to Employment: 25 years of helping young people excel in school—and life
A photo of a group from Bridge to Employment

Bridge to Employment: 25 years of helping young people excel in school—and life

This Johnson & Johnson program pairs high school kids with local companies and institutes of higher learning to help set them up for success in the work world. We take a look at the inspiring statistics behind that success.

Share Article
share to

Since 1992, Johnson & Johnson’s Bridge to Employment (BTE) program has provided high schoolers with meaningful educational experiences and career prep to help set them up for success as they head off to college.

In the last 25 years, BTE has come a long way: What started as a U.S.-based program has expanded well beyond its domestic roots to encompass over 80 sites in more than 20 countries, including India, Israel, Mexico, South Africa and Spain.

Earlier this year, in fact, Johnson & Johnson India was honored with the prestigious Global CSR Leadership Award for Innovation in Corporate Social Responsibility Practices for its work mentoring 50 underprivileged students in Mumbai through the BTE program.

As the latest class of students graduates from the program on June 21, we’re taking a look at the impact BTE has had over the last quarter-century around the globe.


Johnson & Johnson’s Bridge to Employment Program

More from Johnson & Johnson

What to know about We All Belong: 2023 DEI Impact Review

The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.

Giving the gift of sight

In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.

Inside the development of a revolutionary treatment for blood cancers

In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.